Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for MiMedx Group, Inc (MDXG : NSDQ)

• Company Description    MiMedx is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. `Innovations in Regenerative Biomaterials` is the framework behind their mission to give physicians products and tissues to help the body heal itself. Their biomaterial platform technologies include AmnioFix and EpiFix, their tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through their donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. They process the human amniotic membrane utilizing their proprietary PURION Process, to produce a safe and effective implant. Number of Employees: 837

• Price / Volume Information    Yesterday's Closing Price: $5.69 Daily Weekly Monthly 20 Day Moving Average: 827,694 shares Shares Outstanding: 148.10 (millions) Market Capitalization: $842.70 (millions) Beta: 1.57 52 Week High: $9.36 52 Week Low: $5.55 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -19.75% -22.12% 12 Week -15.33% -18.10% Year To Date -15.95% -16.94%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1775 W OAK COMMONS COURT NE - MARIETTA,GA 30062 USA ph: 770-651-9100 fax: 678-384-6741 investorrelations@mimedx.com http://www.mimedx.com

• General Corporate Information    Officers Joseph H. Capper - Chief Executive Officer and Director M. Kathleen Behrens - Chair of the Board Doug Rice - Chief Financial Officer James L. Bierman - Director Cato T. Laurencin - Director Peer Information MiMedx Group, Inc (CORR.) MiMedx Group, Inc (RSPI) MiMedx Group, Inc (CGXP) MiMedx Group, Inc (BGEN) MiMedx Group, Inc (GTBP) MiMedx Group, Inc (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 602496101 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/25/26 Share - Related Items Shares Outstanding: 148.10 Most Recent Split Date: (:1) Beta: 1.57 Market Capitalization: $842.70 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.27 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/25/26

• Fundamental Ratios P/E Current FY Estimate: 21.07 Trailing 12 Months: 14.97 PEG Ratio: - Price Ratios Price/Book: 3.53 Price/Cash Flow: 17.17 Price / Sales: 2.14 EPS Growth vs. Year Ago Period: 114.29% vs. Previous Quarter: 50.00% Sales Growth vs. Year Ago Period: 35.30% vs. Previous Quarter: 15.33% ROE 12/31/25 - - 09/30/25 - 27.19 06/30/25 - 23.03 ROA 12/31/25 - - 09/30/25 - 20.23 06/30/25 - 17.09 Current Ratio 12/31/25 - - 09/30/25 - 4.41 06/30/25 - 4.39 Quick Ratio 12/31/25 - - 09/30/25 - 3.95 06/30/25 - 3.90 Operating Margin 12/31/25 - - 09/30/25 - 14.71 06/30/25 - 12.56 Net Margin 12/31/25 - - 09/30/25 - 10.38 06/30/25 - 8.84 Pre-Tax Margin 12/31/25 - - 09/30/25 - 14.16 06/30/25 - 12.18 Book Value 12/31/25 - - 09/30/25 - 1.61 06/30/25 - 1.46 Inventory Turnover 12/31/25 - - 09/30/25 - 2.86 06/30/25 - 2.78 Debt-to-Equity 12/31/25 - - 09/30/25 - 0.07 06/30/25 - 0.08 Debt-to-Capital 12/31/25 - - 09/30/25 - 6.58 06/30/25 - 7.36

Powered by Zacks Investment Research ©